At 5.5% CAGR, the North America Infectious Disease Diagnostics Market is Projected to be Worth US$ 28,718.07 Million by 2030, Says Business Market Insights

According to Business Market Insights' research, the North America infectious disease diagnostics market was valued at US$ 18,684.43 million in 2022 and is expected to reach US$ 28,718.07 million by 2030, registering a CAGR of 5.5% from 2022 to 2030. Rising number of product approvals and launches and increasing focus on R&D and funding in infectious disease diagnostics are among the critical factors attributed to the North America infectious disease diagnostics market expansion.

The small and big companies operating in the North America infectious disease diagnostics market adopt various strategies such as regional expansion, new product launches, and technological advancements to increase their revenue. Infectious disease diagnostic products are safer and more effective than before with continued developments and technological advancements.

Following are a few recent developments in the North America infectious disease diagnostics market:

• In August 2023, Danaher Corp entered into a definitive agreement to acquire Abcam plc. Danaher would acquire all of the outstanding shares of Abcam for US$ 24.00 per share in cash, or a total enterprise valued of approximately US$ 5.7 billion including assumed indebtedness and net of acquired cash.
  
  
• In January 2022, Cepheid announced that Health Canada had approved the medical device license of Xpert Xpress CoV-2/Flu/RSV plus, a rapid molecular diagnostic test for the qualitative detection of viruses causing Flu A, Flu B, COVID-19, and respiratory syncytial virus (RSV) infections from a single patient sample.
  
  
• In May 2021, Torus Biosystems launched the US$ 25 million program to advance infectious disease diagnostics across healthcare facilities.
  
  
• In December 2021, Roche launched the first infectious illness tests on the Cobas 5800 System, a new molecular laboratory instrument. Cobas HIV-1/HIV-2 Qualitative, Cobas HBV, cobas HCV, cobas HIV-1, and Cobas Omni Utility Channel kit are a few of these options.
  
  
• In June 2021, Bio-Rad Laboratories launched PREvalence ddPCR SARS-CoV-2 Wastewater Quantification Kit, an accurate, sensitive, and cost-effective tool used to detect SARS-CoV-2 in a community's wastewater.
  
  
• In April 2020, CerTest Biotec and B.D. (Becton, Dickinson, and Company) announced that VIASURE SARS-CoV-2 Real-Time PCR Detection Kit adapted for the BD MAX System has been CE marked to the IVD Directive (98/79/C.E.).
  
  
• In November 2020, bioMérieux launched CLARION, its pioneering clinical informatics software that connects diagnostic data in the US.
  
  The active participation of market participants in product innovation and development and an increase in product approvals are likely to boost the growth of the North America infectious disease diagnostics market during the forecast period.
  
  On the contrary, inadequate reimbursement scenario hampers the growth of North America infectious disease diagnostics market.
  
  Based on product, the North America infectious disease diagnostics market is segmented into kits & reagents, instruments, and software & services. The kits & reagents segment held 63.7% share of the North America infectious disease diagnostics market in 2022, amassing US$ 11,897.73 million. It is projected to garner US$ 17,742.90 million by 2030 to expand at 5.1% CAGR during 2022-2030.
  
  By technology, the North America infectious disease diagnostics market is segmented into biosensor-based, immunodiagnostics, molecular-based diagnostic techniques, clinical biology, and others. The immunodiagnostics segment held 44.3% share of the North America infectious disease diagnostics market in 2022, amassing US$ 8,276.31 million. It is projected to garner US$ 12,467.71 million by 2030 to expand at 5.3% CAGR during 2022-2030. The immunodiagnostics segment is further subsegmented into enzyme-linked immunosorbent assay (ELISA), western blotting analysis, and immunofluorescence assay. The molecular-based diagnostic techniques segment is further subsegmented into polymerase chain reaction (PCR), in situ hybridization, isothermal nucleic acid amplification technology (INAAT), next-generation sequencing (NGS), DNA microarrays, and others.
  
  By application type, the North America infectious disease diagnostics market is bifurcated into laboratory testing and point-of-care testing. The laboratory testing segment held 69.5% share of the North America infectious disease diagnostics market in 2022, amassing US 12,989.15 million. It is projected to garner US$ 19,504.36 million by 2030 to expand at 5.2% CAGR during 2022-2030.
  
  By testing type, the North America infectious disease diagnostics market is bifurcated into human testing and veterinary testing. The human testing segment held 82.6% share of the North America infectious disease diagnostics market in 2022, amassing US$ 15,431.62 million. It is projected to garner US$ 23,327.46 million by 2030 to expand at 5.3% CAGR during 2022-2030. The human testing segment is further subsegmented into HIV, hepatitis, HAIs, HPV, tuberculosis, influenza, and others.
  
  By end user, the North America infectious disease diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, research institutes, homecare settings, and others. The diagnostic laboratories segment held 39.9% share of the North America infectious disease diagnostics market in 2022, amassing US 7,459.65 million. It is projected to garner US$ 11,603.54 million by 2030 to expand at 5.7% CAGR during 2022-2030.
  
  Based on country, the North America infectious disease diagnostics market is segmented into US, Canada, and Mexico. The US held 84.2% share of North America infectious disease diagnostics market in 2022, amassing US$ 15,724.81 million. It is projected to garner US$ 23,962.36 million by 2030 to expand at 5.4% CAGR during 2022-2030.
  
  Key players operating in the North America infectious disease diagnostics market are Abbott Laboratories, Bruker Corp, Cardinal Health Inc, F. Hoffmann-La Roche Ltd, Trinity Biotech Plc, Danaher Corp, Bio-Rad Laboratories Inc, ACON Laboratories Inc, and DiaSorin SpA, among others.
  
  
  
  
  Contact Us
  Phone: +16467917070
  Email Id: sales@businessmarketinsights.com